Comparison of ranolazine and trimetazidine on glycemic status in chronic angina patients with diabetes mellitus

Comparison of ranolazine and trimetazidine on glycemic status in chronic angina patients with diabetes mellitus â?? A randomized double blind parallel arm trial - CORANT

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/02/002418

Enrollment

116

Registered

2012-02-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Coronary artery diseaase with diabetes mellitus

Interventions

Intervention1: Ranolazine: 500 mg, twice daily through oral route for 3 months Control Intervention1: Trimetazidine: 35 mg, twice daily through oral route for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either gender, aged >18 yrs • diagnosed with coronary artery disease (documented by coronary angiography / minimum 3 months history of exertional angina) & diabetes mellitus • HbA1C > 7 % • FPG > 126 mg/dl

Exclusion criteria

Exclusion criteria: ï?? MI in the previous 3 months ï?? NYHA Class IV, Severe valvular heart disease, alcoholic cardiomyopathy, those on pacemakers ï?? Patients on drugs known to prolong QT interval eg. Quinidine, dofetilide, sotalol etc ï?? Anaemia ï?? Hypoxemia ï?? Thyrotoxicosis ï?? Hyper viscosity states ï?? Hyper adrenergic states ï?? Aortic stenosis ï?? Renal failure (serum creatinine 2 mg/dl) ï?? Chronic lung disease ï?? Hepatic failure (Elevated liver enzymes defined as ALT, AST or ALP greater than thrice the upper limit of normal). ï?? Pregnancy or absence of contraceptive use in women of child-bearing age. ï?? Patients receiving CYP 3A4 inhibitors eg. Ketoconazole, Diltiazem, Verapamil, Macrolides, Protease Inhibitors etc ï?? Patients on CYP 3A4 inducers eg. rifampicin, barbiturates etc ï?? Patients taking P-glycoprotein inhibitors eg. verapamil, cyclosporine, digoxin etc ï?? Inability to perform stress ECG test ï?? Baseline ECG abnormalities (e.g. Wolffâ??Parkinsonâ??White syndrome, Bundle Branch Block) ï?? Patients participating in other trials

Design outcomes

Primary

Measure	Time frame
1. To study the effect of ranolazine and trimetazidine on HbA1C levels in chronic angina patients with diabetes mellitus. 1. To study the effect of ranolazine and trimetazidine on HbA1C levels in chronic angina patients with diabetes mellitus. 2. To compare the effect of ranolazine and trimetazidine on exercise tolerance in chronic angina patients with diabetes mellitus. Timepoint: one year	—

Secondary

Measure	Time frame
1. To evaluate the effect of ranolazine on Fasting Plasma Glucose (FPG) level in chronic angina patients with concurrent antidiabetic therapy. 2. To find out the need for an increase, decrease or no change in concurrent diabetic therapy in chronic angina patients receiving ranolazine and trimetazidine. 3. To study the effect of ranolazine and trimetazidine on QTc interval in patients with chronic angina. Timepoint: 3 mon	—

Measure

Time frame

1. To evaluate the effect of ranolazine on Fasting Plasma Glucose (FPG) level in chronic angina patients with concurrent antidiabetic therapy. 2. To find out the need for an increase, decrease or no change in concurrent diabetic therapy in chronic angina patients receiving ranolazine and trimetazidine. 3. To study the effect of ranolazine and trimetazidine on QTc interval in patients with chronic angina. Timepoint: 3 mon

—

Countries

India

Contacts

Public ContactSandhiya

JIPMER

steven_d44@rediffmail.com04132296361

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026